Video by PCR via YouTube
Go to Source

Aaysha Cader interviews Rouchelle Sriranjan about the results of the IVORY and IVORY 2 trials. The trials examined low-dose interleukin-2 therapy to reduce arterial inflammation in acute coronary syndrome patients. The study found a 7.7% reduction in arterial inflammation with a positive safety profile and indicated a potential reduction in major adverse cardiovascular events (MACE). The results suggest that this therapy could be added to standard treatment if further trials confirm its efficacy.

More news about the ESC Congress 2024 on PCRonline: https://www.pcronline.com/News/Whats-new-on-PCRonline/2024/ESC/PCRonline-ESC-Congress-2024

Go to Source